Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens

March 26, 2026 4:41 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $132.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found